Regeneron Pharmaceuticals

Tarrytown, United States Founded: 1988 • Age: 38 yrs
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
Request Access

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a company based in Tarrytown (United States) founded in 1988 by Leonard Schleifer.. The company has 15,110 employees as of December 31, 2024. Regeneron Pharmaceuticals has completed 4 acquisitions, including Checkmate Pharmaceuticals, Decibel Therapeutics and LIBTAYO. Regeneron Pharmaceuticals operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.

  • Headquarter Tarrytown, United States
  • Employees 15110 as on 31 Dec, 2024
  • Founders Leonard Schleifer
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Regeneron Pharmaceuticals, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
    $14.2 B
    8.27
    as on Dec 31, 2024
  • Net Profit
    $4.41 B
    11.61
    as on Dec 31, 2024
  • EBITDA
    $4.66 B
    -2.37
    as on Dec 31, 2024
  • Latest Funding Round
    $14.86 M (USD), Grant

    Aug 28, 2010

  • Investors
  • Employee Count
    15110

    as on Dec 31, 2024

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol REGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: REGN . Sector: Health technology · USA
People of Regeneron Pharmaceuticals
Headcount 10000+
Employee Profiles 956
Board Members and Advisors 3
Employee Profiles
People
Nanita Cranford
Vice President, Global Regulatory Operations
People
Kris Sprague
Global Head, Program And Project Planning
People
Zaira Y.
Senior Manager, Global Clinical Operations
People
Leslie Cascone Rohrbacker
Executive Director Human Resources

Unlock access to complete

Board Members and Advisors
people
Tony Coles
Director
people
Kathryn Guarini
Director
people
David P. Schenkein
Director

Unlock access to complete

Funding Insights of Regeneron Pharmaceuticals

  • Total Funding
  • Total Rounds 2
  • Last Round Grant — $14.9M
  • First Round

    (12 Sep 2007)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2010 Amount Grant - Regeneron Pharmaceuticals Valuation

investors

HHS
Sep, 2007 Amount Grant - Regeneron Pharmaceuticals Valuation

investors

HHS
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Regeneron Pharmaceuticals

Regeneron Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Regeneron Pharmaceuticals

Regeneron Pharmaceuticals has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Checkmate Pharmaceuticals, Decibel Therapeutics and LIBTAYO. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Oligonucleotides for cancer immunotherapy are developed via innate immune activation.
2015
Medicines are developed to protect, repair, and restore hearing capacity.
2015
Drug delivery platforms and therapeutics for ophthalmology are developed.
2014
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Regeneron Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Regeneron Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Regeneron Pharmaceuticals

Regeneron Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Therapeutics for rare and ultra-rare metabolic diseases are developed.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Regeneron Pharmaceuticals

Frequently Asked Questions about Regeneron Pharmaceuticals

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988 and raised its 1st funding round 19 years after it was founded.

Where is Regeneron Pharmaceuticals located?

Regeneron Pharmaceuticals is headquartered in Tarrytown, United States. It is registered at Tarrytown, New York, United States.

Who is the current CEO of Regeneron Pharmaceuticals?

Leonard Schleifer is the current CEO of Regeneron Pharmaceuticals. They have also founded this company.

How many employees does Regeneron Pharmaceuticals have?

As of Dec 31, 2024, the latest employee count at Regeneron Pharmaceuticals is 15,110.

What is the annual revenue of Regeneron Pharmaceuticals?

Annual revenue of Regeneron Pharmaceuticals is $14.2B as on Dec 31, 2024.

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, United States. Antibodies are developed by the company for applications in oncology, ophthalmology, and immunology. Key products include ARCALYST for inflammation, EYLEA for eye conditions, and PRALUENT as a PCSK9 inhibitor. Phase 3 and 2 pipelines address rheumatoid arthritis, asthma, atopic dermatitis, and other disorders. Annual revenues reached 12.17 billion in 2022, with net profit at 4.33 billion.

Who are the top competitors of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals's top competitors include Moderna, BeiGene and Annexon.

Is Regeneron Pharmaceuticals publicly traded?

Yes, Regeneron Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol REGN.

How many acquisitions has Regeneron Pharmaceuticals made?

Regeneron Pharmaceuticals has made 4 acquisitions, including Checkmate Pharmaceuticals, Decibel Therapeutics, and LIBTAYO.

Who are Regeneron Pharmaceuticals's investors?

Regeneron Pharmaceuticals has 1 investor. Key investors include HHS.

What is Regeneron Pharmaceuticals's ticker symbol?

The ticker symbol of Regeneron Pharmaceuticals is REGN on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available